GlassScriptPhysician profile
Glenan Rodriguez
NPI 1295235323
$711.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.29 · 2022: $282 · 2023: $262 · 2024: $84.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $97.76 | 2023 | Elahere |
| Novartis Pharmaceuticals Corporation | $93.96 | 2021-2023 | |
| Astellas Pharma US INC | $64.41 | 2022-2023 | Padcev |
| Amgen INC. | $64.10 | 2021-2022 | |
| Abbvie INC. | $61.97 | 2024 | |
| Seagen INC. | $57.58 | 2022-2023 | Tivdak, Padcev |
| Taiho Oncology, INC. | $41.75 | 2023-2024 | |
| Emd Serono, INC. | $41.05 | 2022-2023 | Bavencio |
| Genentech USA, INC. | $31.53 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $30.44 | 2021 | |
| Incyte Corporation | $29.65 | 2023 | Jakafi |
| Sumitomo Pharma America, INC. | $23.62 | 2023 | Myfembree |
| Astrazeneca Pharmaceuticals LP | $20.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.63 | 2022 | |
| Lilly USA, LLC | $17.33 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $17.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenan Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.